Heterogeneidade na apresentação clínica de fraturas atípicas após uso prolongado de bisfosfonatos – Fatores de risco e marcadores de remodelação óssea

Piazzetta, Giovana; Baracho, Filipe Ribas; Oliveira, Larissa Bertacchini de; Santos, Gustavo Rengel dos; Kulak, Carolina A. M.; Borba, Victória Zeghbi Cochenski

doi:10.1590/0004-2730000003229

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other medications may also be related to the suppression of bone remodeling, such as estrogens, glucocorticoids and/or proton-pump inhibitors. [3][4][5] Multiple reports within the literature indicate a probable relationship between the use of bisphosphonates and the increase of nonosteoporotic femur fractures with atypical patterns in patients medicated for six years or more with this class of drug. The first case of this association was reported in 2005.…”

Section: Introductionmentioning

confidence: 99%

Atypical Femoral Fractures Due to the Use of Bisphosphonates: Epidemiologic Study in a Tertiary Hospital

GOLFIERI¹,

ZANON

PERCIO³

2022

Acta ortop. bras.

View full text Add to dashboard Cite

Objective: Show the relationship between atypical femoral fractures and prolonged use of bisphosphonates and analyze the limit of its beneficial use. Methods: Retrospective cohort study (level of evidence 2B). From Atypical fracture cases, patients who used bisphosphonates were selected and the time period of their use was analyzed. Additionally, the variables sex, age, and the side most affected were studied. Results: Nine atypical femur fractures were found, all associated with the use of bisphosphonates. The average period of use of this medication was nine years (minimum of three years; maximum of 14 years). The patients’ mean age was of 78 years (69-88 years) and all were women, with the right member being the most affected. Conclusion: The use of bisphosphonates to prevent osteoporotic fractures has been increasingly frequent and, when used for a prolonged period, it has been related to atypical fractures. Further scientific studies on doses, maximum periods of treatment, and risk-benefit in the indication of these medications are needed to assist in therapeutic management for each case. Level of Evidence II, Retrospective Study.

show abstract

Section: Introductionmentioning

confidence: 99%